Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9484797 | 0.81 | HPGD (0.43) | MAPTNPC1RAB9AGAAKMT2A | |
| SCHEMBL8786917 | 0.80 | PTPN1 (0.41) | KMT2AMEN1 | |
| SCHEMBL9483366 | 0.79 | SRD5A2 (0.41) | NPC1KMT2AALOX15ALDH1A1 | |
| SCHEMBL9484633 | 0.79 | HSD17B3 (0.44) | L3MBTL1 | |
| SCHEMBL9483334 | 0.79 | ALDH1A1 (0.48) | MAPTNPC1RAB9AGAAKMT2A | |
| SCHEMBL9685893 | 0.78 | CNR2 (0.36) | — | |
| SCHEMBL9483714 | 0.77 | ALDH1A1 (0.33) | MAPTNPC1RAB9AGAAKDM4E | |
| SCHEMBL9684034 | 0.76 | ALDH1A1 (0.32) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL9484177 | 0.75 | HPGD (0.45) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7765516 | 0.70 | RECQL (0.31) | RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1502590-B1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | SERVIER LAB (FR) | 2006-12-20 | — | — | EP | disclosed |
| US-7071221-B2 | Heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2006-07-04 | — | — | US | disclosed |
| US-20050026973-A1 | New heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2005-02-03 | — | — | US | disclosed |
| EP-1502590-A1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | Les Laboratoires Servier (FR) | 2005-02-02 | — | — | EP | disclosed |
| EP-0463945-B1 | Chalcone derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-12-27 | — | — | EP | disclosed |
| US-5240949-A | Analgesics, blood lipid normalizing | ADIR ET COMPAGNIE (FR) | 1993-08-31 | — | — | US | disclosed |
| US-5179091-A | Anti-inflammatory; antioxidant | ADIR ET COMPAGNIE (FR) | 1993-01-12 | — | — | US | disclosed |
| US-5162350-A | Analgesics; nontoxic; side effect reduction | ADIR ET COMPAGNIE (FR) | 1992-11-10 | — | — | US | disclosed |
| EP-0463945-A1 | Chalcone derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026973-A1 | New heterocyclic oxime compounds | CBR3, CBR1, CYB5R3 | MAPT 4285/4885NPC1 4385/4885RAB9A 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.